About
CRISPR-Cas9 therapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
11
As Collaborator
5
Total Enrollment
1,325
By Phase
PHASE1: 5PHASE1/PHASE2: 5PHASE3: 3PHASE2/PHASE3: 2
By Status
RECRUITING: 7TERMINATED: 4ENROLLING_BY_INVITATION: 2COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
Today
Hover over trial bars to see details
Recent Trials
NCT06925542Lead Sponsor
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
PHASE1Recruiting
80 participants
Started: Mar 10, 2025 · Completed: Dec 31, 2031
NCT06492304Lead Sponsor
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
PHASE1/PHASE2Recruiting
290 participants
Started: Aug 13, 2024 · Completed: Nov 30, 2030
NCT06208878Lead Sponsor
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
N/AEnrolling by invitation
70 participants
Started: Nov 22, 2023 · Completed: Aug 31, 2038
NCT05795595Lead Sponsor
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
PHASE1/PHASE2Recruiting
250 participants
Started: Mar 13, 2023 · Completed: May 31, 2030
NCT05643742Lead Sponsor
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
PHASE1/PHASE2Recruiting
120 participants
Started: Mar 10, 2023 · Completed: Feb 28, 2030
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...